EP0181001B1 - Polypeptid, dessen Verfahren zur Herstellung und dieses enthaltende pharmazeutische Zusammensetzung und deren Benutzung - Google Patents

Polypeptid, dessen Verfahren zur Herstellung und dieses enthaltende pharmazeutische Zusammensetzung und deren Benutzung Download PDF

Info

Publication number
EP0181001B1
EP0181001B1 EP85114226A EP85114226A EP0181001B1 EP 0181001 B1 EP0181001 B1 EP 0181001B1 EP 85114226 A EP85114226 A EP 85114226A EP 85114226 A EP85114226 A EP 85114226A EP 0181001 B1 EP0181001 B1 EP 0181001B1
Authority
EP
European Patent Office
Prior art keywords
polypeptide
met
same
groups
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP85114226A
Other languages
English (en)
French (fr)
Other versions
EP0181001A2 (de
EP0181001A3 (en
Inventor
Hiroshi Yoshino
Yutaka Tsuchiya
Takeru Kaneko
Takahiro Nakazawa
Masuhiro Ikeda
Shin Araki
Kiyomi Yamatsu
Shinro Tachibana
Yoshihiro Arakawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Priority to EP94107769A priority Critical patent/EP0614913A3/de
Publication of EP0181001A2 publication Critical patent/EP0181001A2/de
Publication of EP0181001A3 publication Critical patent/EP0181001A3/en
Application granted granted Critical
Publication of EP0181001B1 publication Critical patent/EP0181001B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/675—Beta-endorphins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Definitions

  • the present invention relates to polypeptides having excellent medicinal effects, a process for preparing the same, a pharmaceutical composition containing the same as well as the use thereof.
  • the invention relates to polypeptides of the following general formula (I): wherein R1 and R can be the same or different and each is selected from hydrogen, lower alkyl groups having 1 to 6 carbon atoms or lower alkenyl groups having 2 to 6 carbon atoms,
  • amino acids constituting the peptides herein include D- and L-amino acids. Unless otherwise stated, the amino acids are L-amino acids.
  • the symbols used herein have the same meanings as is the general practice in the field of peptide chemistry. Namely, they are as follows:
  • dynorphin is an opioid peptide of the following structural formula found by some of the inventors of the present invention:
  • Dynorphin is a natural opioid peptide having specific effects on a K-receptor and, therefore, the use of it as an analgesic having no side effects, such as tolerance or dependency, is expected.
  • dynorphin has the defect that it cannot exhibit an analgesic effect, as such, when it is administered by intravenous injection, because it is unstable in the blood.
  • dynorphin is a heptadecapeptide having a relatively long chain.
  • the inventors have made intensive investigations of peptides having chains shorter than that of dynorphin and capable of exhibiting an analgesic effect, when administered by both intravenous and subcutaneous injection, and finally have discovered that this object can be attained by using peptides of the following formula (I) comprising 7 amino acids.
  • the present invention provides polypeptides of the following general formula: wherein R1 and R can be the same or different and each is selected from hydrogen, lower alkyl groups having 1 to 6 carbon atoms or lower alkenyl groups having 2 to 6 carbon atoms,
  • Examples of the pharmacologically acceptable salts herein include inorganic acid salts, such as hydrochloride, sulfate, hydrobromide and hydroiodide, as well as organic acid salts, such as maleate, fumarate, succinate, acetate, malonate, citrate and benzoate.
  • inorganic acid salts such as hydrochloride, sulfate, hydrobromide and hydroiodide
  • organic acid salts such as maleate, fumarate, succinate, acetate, malonate, citrate and benzoate.
  • an object of the present invention is to provide new peptides useful as medicines, particularly analgesics.
  • Another object of the invention is to provide a process for producing new peptides useful as medicines.
  • Still another object of the invention is to provide new analgesics containing the new peptides.
  • lower alkyl group in the above-mentioned definition of R1 to R13 refers to straight-chain, branched, cyclic or ring-containing alkyl groups having 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, 1-methylpropyl, tert-butyl, cyclopropylmethyl, n-pentyl, 1-ethylpropyl, isoamyl and n-hexyl groups.
  • lower alkenyl group in the above-mentioned definition of R1 and R refers to those corresponding to the above-mentioned alkyl groups but having a double bond in some position.
  • alkyl in the ' ⁇ -N-alkyl derivatives' in the definition of the amino acids has the same meaning as that of the above-mentioned lower alkyl group.
  • the compounds of the present invention in which at least one of the constituent amino acids is an ⁇ -N-alkylamino acid or a D-amino acid are free from the serious defects of dynorphin and its derivatives, namely, that they cannot exhibit any analgesic effects, as such, when they are administered by intravenous injection, because they are unstable in the blood.
  • the compounds of the invention are highly valuable because they have a high stability in vivo and they are practically useful as analgesics.
  • the peptides of the present invention can be synthesized by any suitable process.
  • the protected peptides can be synthesized by a conventional liquid phase process or solid phase process. It is usually preferred that functional groups present in side chains of the amino acids are protected. All the protective groups are removed in the final stage.
  • the protective groups for the functional groups in the side chains of the amino acids include all the protective groups reported in the prior art. Typical examples of them include tosyl (Tos), nitro (NO2), benzyl (Bzl), tert-butyl (But), benzyloxycarbonyl (Z) and tert-butoxycarbonyl (BOC) groups.
  • the protective groups for the ⁇ -amino groups in the amino acids all of the protective groups reported in the prior art can be used. It is preferred, however, to select the combination of the protective groups so that the protective groups for only the ⁇ -amino groups can be removed selectively without exerting any influence on the protective groups for the functional groups in the side chains.
  • a tert-butoxycarbonyl group is used as the protective group for the ⁇ -amino group
  • a benzyl or benzyloxycarbonyl group is preferred for protecting the functional group(s) in the side chain(s).
  • the protected peptide is synthesized preferably by a stepwise process wherein all the amino acids are bonded in sequence starting from the C-terminal, or a process wherein the fragment condensation is conducted at the position of Gly. It is also possible to conduct the fragment condensation at any desired position.
  • the protective groups are removed from the peptide and the latter is purified by repeating the reactions of the following schemes to synthesize the peptide.
  • the steps of this process will be illustrated with reference to the liquid phase process: wherein X1 and X each represent H or an alkyl group, Y1 and Y each represent an amino acid side chain and R' and R" represent a protective group or a peptide residue.
  • the peptide bond can be formed by any of the processes reported heretofore.
  • a conventional process comprises activating the carboxyl group of an acid component of the general formula: by a conventional method, such as the azide method, dicyclohexylcarbodiimide (DCC) method, mixed anhydride method or active ester method and reacting the activated compound with an amine component of the general formula:
  • the reaction conditions such as reaction solvent and temperature, can vary depending on the method chosen for activating the carboxyl group.
  • the mixed anhydride method which is one of typical condensation methods, is carried out as follows: an acid component of the general formula: is dissolved in an aprotic solvent, such as dimethylformamide, tetrahydrofuran or ethyl acetate, the resulting solution is cooled to about -20°C and then equimolar amounts of N-methylmorpholine and ethyl chlorocarbonate are added successively to the solution. After 5 min, an amine component of the general formula: in an equimolar amount is added thereto and the mixture is stirred at -15 to 0°C for 2 to 5 h and then treated in a conventional manner to obtain a protected peptide of the general formula:
  • an aprotic solvent such as dimethylformamide, tetrahydrofuran or ethyl acetate
  • the removal of a protective group is carried out by a conventional process, such as a catalytic reduction process, a process wherein an acid is used, a process wherein a base is used and a process wherein hydrazine is used.
  • a preferred process is selected from among these processes depending on the type of the protective group employed for the ⁇ -amino group.
  • Typical processes include one wherein the protective group is removed by the catalytic reduction of the benzyloxycarbonyl group and one wherein the tert-butoxycarbonyl group is removed with trifluoroacetic acid.
  • the protective groups are removed by a conventional process, such as a catalytic reduction process, a process wherein a liquid ammonia/alkali metal is used, a process wherein an acid is used, a process wherein a base is used or a process wherein hydrazine is used. In practice, the process is selected depending on the type of the protective group that is to be removed.
  • One of the frequently employed processes comprises removing the protective group with hydrogen fluoride (HF) as follows: 1 g of a protected peptide is dissolved in about 30 ml of HF, in the presence of 0.5 ml of anisole, at -15 to 0°C, in a closed reaction vessel. The solution is stirred for 60 min and HF is distilled out of the reaction system. The residue is washed with ether and dissolved in water. The solution is treated with Amberlite IRA-93 (acetic acid type) and freeze-dried to obtain a crude peptide from which the protective groups have been removed.
  • HF hydrogen fluoride
  • the crude peptide may be purified by a conventional process such as ion exchange chromatography, gel filtration, partition chromatography, counter current distribution and high performance liquid chromatography.
  • the purification is conducted by, for example, the following high performance liquid chromatography: 100 mg of the crude peptide is charged in a column having a diameter of 20 mm and a height of 250 mm containing Nucleosil 5 c 18 as the carrier and then eluted with 0.05% HCl (H2O-CH3CN). Fractions having peaks corresponding to the intended peptide were collected by detection at UV 210 nm and freeze-dried to obtain the intended peptide.
  • the compounds of the present invention exhibit a very potent activity as compared with dynorphin A.
  • the peptide compounds obtained by the present invention have opioid activities similar to those of dynorphin, their effects are quite strong and remarkable analgesic effects are exhibited by intravenous injection or subcutaneous injection.
  • the compounds of the present invention exhibit strong analgesic effects upon systemic administration by intravenous or subcutaneous injection, whereas dynorphin and its derivatives so far reported, scarcely exhibit analgesic effects upon intravenous injection because they are unstable in the blood.
  • the peptide compounds obtained by the process of the present invention have remarkable analgesic effects and they are useful as medicines in the therapeutical field.
  • the compounds of the present invention are given by peroral or parenteral administration. Usually, they are given parenterally in the form of intravenous, subcutaneous or intramuscular injection or suppositories or sublingual tablets.
  • the dosage varies depending on the severity of the symptoms, age of the patient, sex, body weight, sensitivity, administration manner, stage of the disease, intervals, properties of the medical preparation, formulation, type of preparation and type of the active ingredient. Although the dosage is thus not particularly limited, it is usually about 0.1 to 1,000 mg/day, preferably about 1 to 300 mg/day, for adult human beings.
  • the compounds of the present invention can be formulated into injections, suppositories, sublingual tablets, tablets and capsules by conventional processes used in the field of pharmacology.
  • additives such as a pH controller, buffering agent, suspending agent, solubilizer, stabilizer, isotonizing agent and preservative are added to the active ingredient and the obtained mixture is formulated into an intravenous, subcutaneous or intramuscular injection liquid by a conventional method. If necessary, the mixture may be lyophilized by conventional methods.
  • suspending agents examples include methylcellulose, Polysorbate 60, hydroxyethylcellulose, acacia, tragacanth powder, sodium carboxymethylcellulose and polyoxyethylene sorbitan monolaurate.
  • solubilizers examples include polyoxyethylene hardened castor oil, Polysorbate 80, nicotinamide, polyoxyethylene sorbitan monolaurate, macrogol and ethyl esters of castor oil fatty acids.
  • Examples of the stabilizers include sodium sulfite, sodium metasulfite and ethers.
  • Examples of the preservatives include methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, sorbic acid, phenol, cresol and chlorocresol.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (3)

  1. Polypeptide mit der Formel (I):
    Figure imgb0015
     worin R¹ und R gleich oder verschieden sein können, und jeweils ausgewählt sind aus Wasserstoff, Niederalkylgruppen mit 1 bis 6 Kohlenstoffatomen oder Niederalkenylgruppen mit 2 bis 6 Kohlenstoffatomen,
    A ist ausgewählt aus D-Met, D-Ser oder D-Thr,
    C ist ausgewählt aus L-Leu, L-Ile, L-Nle, L-tertLeu, L-Met, L-Met(O), L-Ser oder L-Val,
    D und E können gleich oder verschieden sein und sind jeweils ausgewählt aus L-Arg, L-Lys, L-homoArg oder L-Orn und
    F ist ausgewählt aus -OH oder -NH₂
       oder ein pharmazeutisch verträgliches Salz des Polypeptids, welches die Bildung eines Polypeptids mit einer Struktur der obigen Formel umfaßt, jedoch in der die reaktiven Gruppen durch Schutzgruppen geschützt sind, anschließendes Entfernen der Schutzgruppen unter Erhalt eines Polypeptids mit der obigen Formel.
  2. verfahren zur Herstellung einer analgetischen Zusammensetzung, dadurch gekennzeichnet, daß als Wirkstoff eine therapeutisch wirksame Menge des Polypeptids der allgemeinen Formel (I), worin R¹ und R gleich oder verschieden sein können, und jeweils ausgewählt sind aus Wasserstoff, Niederalkylgruppen mit 1 bis 6 Kohlenstoffatomen oder Niederalkenylgruppen mit 2 bis 6 Kohlenstoffatomen,
    A ist ausgewählt aus D-Met, D-Ser oder D-Thr,
    C ist ausgewählt aus L-Leu, L-Ile, L-Nle, L-tertLeu, L-Met, L-Met(O), L-Ser oder L-Val,
    D und E können gleich oder verschieden sein und sind jeweils ausgewählt aus L-Arg, L-Lys, L-homoArg oder L-Orn und
    F ist ausgewählt aus -OH oder -NH₂ oder ein pharmazeutisch verträgliches Salz des Polypeptids, mit einem pharmazeutisch verträglichen Vehikel kombiniert wird.
  3. Verwendung der Polypeptide, erhalten durch ein Verfahren nach Anspruch 1, zur Herstellung einer pharmazeutischen Zusammensetzung, die als Analgetikum geeignet ist.
EP85114226A 1984-11-09 1985-11-08 Polypeptid, dessen Verfahren zur Herstellung und dieses enthaltende pharmazeutische Zusammensetzung und deren Benutzung Expired - Lifetime EP0181001B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP94107769A EP0614913A3 (de) 1984-11-09 1985-11-08 Dynorphin Derivate.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP236076/84 1984-11-09
JP59236076A JPH0680079B2 (ja) 1984-11-09 1984-11-09 ポリペプチド

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP94107769.5 Division-Into 1985-11-08

Publications (3)

Publication Number Publication Date
EP0181001A2 EP0181001A2 (de) 1986-05-14
EP0181001A3 EP0181001A3 (en) 1989-04-19
EP0181001B1 true EP0181001B1 (de) 1996-03-20

Family

ID=16995360

Family Applications (2)

Application Number Title Priority Date Filing Date
EP85114226A Expired - Lifetime EP0181001B1 (de) 1984-11-09 1985-11-08 Polypeptid, dessen Verfahren zur Herstellung und dieses enthaltende pharmazeutische Zusammensetzung und deren Benutzung
EP94107769A Withdrawn EP0614913A3 (de) 1984-11-09 1985-11-08 Dynorphin Derivate.

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP94107769A Withdrawn EP0614913A3 (de) 1984-11-09 1985-11-08 Dynorphin Derivate.

Country Status (21)

Country Link
US (1) US4707468A (de)
EP (2) EP0181001B1 (de)
JP (1) JPH0680079B2 (de)
KR (1) KR880000765B1 (de)
CN (1) CN1029684C (de)
AT (1) ATE135712T1 (de)
AU (1) AU588837B2 (de)
CA (1) CA1267997A (de)
DE (1) DE3588095T2 (de)
DK (1) DK171300B1 (de)
ES (1) ES8800272A1 (de)
FI (1) FI92935C (de)
GR (1) GR852689B (de)
HU (1) HU203563B (de)
IL (1) IL76924A (de)
NO (1) NO169347C (de)
NZ (1) NZ214122A (de)
PH (1) PH23847A (de)
PT (1) PT81441B (de)
SU (1) SU1433415A3 (de)
ZA (1) ZA858456B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2673376A1 (fr) * 1991-03-01 1992-09-04 Lefesvre Andre Composition pharmaceutique pour le traitement des tumeurs de kaposi.
US5817628A (en) * 1992-12-02 1998-10-06 The Rockefeller University Dynorphin a suppression of natural killer cell activity
SE9401596D0 (sv) * 1994-05-06 1994-05-06 Astra Ab New compounds
JP3385147B2 (ja) * 1996-01-31 2003-03-10 ユニ・チャーム株式会社 男性用尿とり袋
WO1997049422A1 (en) * 1996-06-24 1997-12-31 The Rockefeller University Method of using ligands of the kappa opioid receptor
IL138214A0 (en) * 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6232287B1 (en) * 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
IL137820A (en) * 2000-08-10 2009-06-15 S I S Shulov Inst For Science Pharmaceutical composition for topical administration comprising an analgesic peptide
PT1486206E (pt) * 2000-08-25 2008-01-25 Res Corp Technologies Inc ¿utilizações para aminoácidos anticonvulsivantes para o tratamento de perturbações bipolares¿
DE60120104T2 (de) * 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
PT1243263E (pt) * 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
US7622446B2 (en) * 2001-04-18 2009-11-24 The Open University Polypeptides, derivatives and uses thereof
US7491702B2 (en) * 2001-04-18 2009-02-17 The Open University Polypeptides related to amyloid precursor protein, pharmaceutical compositions thereof, and methods of treatment using the same
US8008351B2 (en) 2004-04-16 2011-08-30 Ucb Pharma Gmbh Methods for prophylaxis or treatment of conditions associated with cortical spreading depression
EP1781276B1 (de) * 2004-08-27 2010-06-23 UCB Pharma GmbH Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (de) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie
GB2432586B (en) * 2005-11-25 2010-01-13 Univ Open Treatment of neurodegenerative disorders
EA027836B1 (ru) * 2006-06-15 2017-09-29 ЮСиБи ФАРМА ГМБХ Фармацевтическая комбинация для профилактики, облегчения и/или лечения приступов эпилепсии и ее применение
RU2010114029A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Астрессин и бета-эндорфин для применения в качестве терапевтических средств
CA2698985A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
CN111182887A (zh) * 2017-06-14 2020-05-19 株式会社生物解决方案有限公司 用于改善皮肤皱纹或抗炎活性的包括物质p的化妆品组合物
EP4092038A1 (de) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioidagonistpeptide und verwendungen davon
AU2021300202A1 (en) * 2020-07-01 2023-02-02 PreveCeutical Medical Inc. Peptides and uses thereof
RU2760133C1 (ru) * 2021-04-22 2021-11-22 Федеральное государственное бюджетное учреждение науки "Научный центр биомедицинских технологий Федерального медико-биологического агентства". Амиды гептапептида для лечения HMGB1-зависимых заболеваний

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2703109A1 (de) * 1976-01-26 1977-08-04 Wellcome Found Biologisch wirksame amide
US4254106A (en) * 1976-01-26 1981-03-03 Burroughs Wellcome Co. Biologically active amides
US4123523A (en) * 1976-06-21 1978-10-31 Imperial Chemical Industries Limited Analgesic and sedative polypeptides
US4371463A (en) * 1977-02-17 1983-02-01 The United States Of America As Represented By The Department Of Health And Human Services Enzyme-resistant opiate pentapeptides
US4081434A (en) * 1977-03-11 1978-03-28 Hoffmann-La Roche Inc. Novel analogs of β-endorphin
US4139504A (en) * 1977-06-16 1979-02-13 Coy David Howard Novel nonapeptides, intermediates therefor, and compositions and methods employing said nonapeptides
US4127533A (en) * 1977-06-16 1978-11-28 Coy David Howard Novel octapeptides, intermediates therefor, and compositions and methods employing said octapeptides
GB1604850A (en) * 1977-11-24 1981-12-16 Wellcome Found Biologically active peptides
US4148786A (en) * 1978-06-26 1979-04-10 American Home Products Corporation Analgesic polypeptide
US4178284A (en) * 1978-12-11 1979-12-11 American Home Products Corporation Octapeptides
DE2936099A1 (de) * 1979-09-06 1981-04-02 Victor Dipl.- Chem. 8000 München Brantl Pharmakologisch aktive peptide
DE3163199D1 (en) * 1980-07-17 1984-05-24 Sandoz Ag Novel pentapeptides, processes for their production, pharmaceutical compositions comprising said pentapeptides and their use
JPS57134451A (en) * 1981-02-13 1982-08-19 Suntory Ltd Peptide opioide
DE3274798D1 (en) * 1981-10-05 1987-02-05 Nicholas P Plotnikoff Process for using endorphins as antitumour agents
US4462941A (en) * 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
JPS59141547A (ja) * 1983-02-01 1984-08-14 Eisai Co Ltd 鎮痛作用を有する新規ペプタイドおよび製法
US4518711A (en) * 1983-05-16 1985-05-21 Gibson-Stephens Institute Conformationally constrained cyclic enkephalin analogs with delta receptor specificity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BACHEM information sheet BA 040/2 (Jan. 1989) *

Also Published As

Publication number Publication date
DE3588095T2 (de) 1996-09-19
CN1029684C (zh) 1995-09-06
PT81441B (pt) 1987-11-11
US4707468A (en) 1987-11-17
ES548667A0 (es) 1987-10-16
JPH0680079B2 (ja) 1994-10-12
NO169347B (no) 1992-03-02
ES8800272A1 (es) 1987-10-16
KR860004081A (ko) 1986-06-16
SU1433415A3 (ru) 1988-10-23
EP0614913A3 (de) 1997-06-04
PH23847A (en) 1989-11-23
ZA858456B (en) 1987-07-29
EP0181001A2 (de) 1986-05-14
ATE135712T1 (de) 1996-04-15
FI92935C (fi) 1995-01-25
JPS61115097A (ja) 1986-06-02
DK171300B1 (da) 1996-08-26
DK513385D0 (da) 1985-11-07
HU203563B (en) 1991-08-28
NO854435L (no) 1986-05-12
NZ214122A (en) 1988-08-30
FI854227L (fi) 1986-05-10
IL76924A (en) 1990-07-12
KR880000765B1 (en) 1988-05-06
PT81441A (en) 1985-12-01
EP0181001A3 (en) 1989-04-19
HUT40145A (en) 1986-11-28
IL76924A0 (en) 1986-04-29
AU4938985A (en) 1986-05-15
GR852689B (de) 1986-02-21
DK513385A (da) 1986-05-10
FI854227A0 (fi) 1985-10-28
FI92935B (fi) 1994-10-14
CN85109722A (zh) 1986-10-08
DE3588095D1 (de) 1996-04-25
NO169347C (no) 1992-06-10
AU588837B2 (en) 1989-09-28
CA1267997A (en) 1990-04-17
EP0614913A2 (de) 1994-09-14

Similar Documents

Publication Publication Date Title
EP0181001B1 (de) Polypeptid, dessen Verfahren zur Herstellung und dieses enthaltende pharmazeutische Zusammensetzung und deren Benutzung
US4024248A (en) Peptides having LH-RH/FSH-RH activity
EP1098906B1 (de) Pacap-peptidanaloga
CA2252458A1 (en) Conjugates of lipophilic moieties and fragments of vasoactive intestinal peptide (vip)
EP0014230B1 (de) Undecapeptid, seine Säurezusatzsalze und seine pharmazeutischen Zusammensetzungen
JP2837352B2 (ja) 胃腸運動活性を抑制するモチリン類似ポリペプチド
WO1997042223A9 (en) hGH-RH(1-29)NH2 ANALOGUES HAVING ANTAGONISTIC ACTIVITY
EP0050503B1 (de) Pharmakologisch wirksame Pentapeptid Derivate
EP0350318A2 (de) Peptide
EP0333071A2 (de) Polypeptide, deren Methoden zur Herstellung, sie enthaltende pharmazeutische Zusammensetzungen und Verwendung
AU8237187A (en) Derivatives of atrial natriuretic peptides
EP0516851B1 (de) Physiologisch aktive substanzen, die gut zum durchdringen biologischer membranen befähigt sind
JPH0770178A (ja) 胃腸運動刺激活性を有するモチリン類似ポリペプチド
EP0755942B1 (de) N-amidino- dermorphin-derivat
HU185230B (en) Process for producing pharmacologically active encephaline analogous peptides
EP0431113A1 (de) Atriale peptidderivate
JPS642600B2 (de)
JPH051798B2 (de)
EP0101929A1 (de) Diester von Polypeptiden, ihre Herstellung und Verwendung
US4579841A (en) Dipeptide derivatives having opiate activity
AU718320B2 (en) Peptide derivatives
US6228841B1 (en) Peptide derivatives
EP0115850B1 (de) Peptiden, Verfahren zur deren Herstellung und deren pharmazeutische Zusammensetzungen
EP0175323B1 (de) Biologisch aktive Peptide, deren Verfahren zur Herstellung und pharmazeutische Zusammensetzungen
US4216128A (en) Enkephalin analogues

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LI NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LI NL SE

17P Request for examination filed

Effective date: 19890517

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EISAI CO., LTD.

17Q First examination report despatched

Effective date: 19910122

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

ITF It: translation for a ep patent filed

Owner name: FUMERO BREVETTI S.N.C.

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI NL SE

REF Corresponds to:

Ref document number: 135712

Country of ref document: AT

Date of ref document: 19960415

Kind code of ref document: T

XX Miscellaneous (additional remarks)

Free format text: TEILANMELDUNG 94107769.5 EINGEREICHT AM 08/11/85.

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: MICHELI & CIE INGENIEURS-CONSEILS

REF Corresponds to:

Ref document number: 3588095

Country of ref document: DE

Date of ref document: 19960425

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19981105

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19981110

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19981112

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19981113

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19981116

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19981120

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19981126

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19990119

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991108

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991108

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991109

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991130

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991130

BERE Be: lapsed

Owner name: EISAI CO. LTD

Effective date: 19991130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000601

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19991108

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

EUG Se: european patent has lapsed

Ref document number: 85114226.5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000731

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20000601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000901

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST